

Title: HS-20137 for Chinese moderate-to-severe psoriasis: a randomized, double-blinded, phase 2 study

Running title: Phase 2 study of HS-20137 in psoriasis

Lin Cai, PhD¹, Xiaohua Wang, PhD², Litao Zhang, PhD³, Guoqiang Zhang, PhD⁴, Liming Wu, PhD⁵, Baoqi Yang, MD⁶, Zudong Meng, PhD⁷, Jihai Shi, PhD⁸, Guangming Han, PhD⁹, Aihua Wei, PhD¹⁰, Shanshan Li, PhD¹¹, Yi Zhao, PhD¹², Juan Su, PhD¹³, Nianjin Wei, PhD¹⁴, Siying Liu, PhD¹⁵, Ran Liu, PhD¹⁵, Wei Liu, PhD¹⁵, Min Fang, PhD¹⁴, Xiaoqing Zhang, PhD¹⁵, Jianzhong Zhang, PhD^{1*},

Affiliations

¹Department of Dermatology, Peking University People's Hospital, Beijing, China

²Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China

³Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

⁴Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, China

⁵Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China

⁶Department of Dermatology, Dermatology Hospital of Shandong First Medical University & Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, China

⁷Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China

⁸Department of Dermatology, The First Affiliated Hospital of Baotou Medical College, Baotou, China

⁹Department of Dermatology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan, China

¹⁰Department of Dermatology, Beijing Tongren Hospital, Beijing, China

¹¹Department of Dermatology, The First Hospital of Jilin University, Changchun, China

¹²Department of Dermatology, Beijing Tsinghua Changgung Hospital, Beijing, China

¹³Department of Dermatology, Xiangya Hospital of Central South University, Changsha, China

¹⁴Medical Department, Qyuns Therapeutics Co., Ltd, Taizhou, China

¹⁵Clinical Development Center, Shanghai Hansoh BioMedical Co., Ltd, Shanghai, China

*Corresponding author: Jianzhong Zhang, PhD

Department of Dermatology, Peking University People's Hospital, No.11, Xizhimen South Street Beijing, China.

Email: rmzjz@126.com

Online-Only Supplements

- Figure S1. PASI score through 52 weeks.
- Table S1. Secondary efficacy endpoints through 52 weeks.

Figure S1. PASI score through 52 weeks. The missing data on PASI score was handled by last observation carried forward method. PASI, Psoriasis Area and Severity Index; Q8W, receive HS-20137 every 8 week after first 2 injections; Q12W, receive HS-20137 every 12 week after first 2 injections.




Table S1. Secondary efficacy endpoints through 52 weeks.

Efficacy	Placebo- 200mg	100mg Q8W- 200mg	200mg Q8W	200mg Q12W-
PASI 75				
Week 16	5 (12.5)	32 (80.0)	36 (92.3)	35 (87.5)
Week 28	32 (80.0)	38 (95.0)	37 (94.9)	35 (87.5)
Week 44	36 (90.0)	39 (97.5)	37 (94.9)	37 (92.5)
IGA 0/1				
Week 16	5 (12.5)	30 (75.0)	27 (69.2)	30 (75.0)
Week 28	26 (65.0)	34 (85.0)	30 (76.9)	32 (80.0)
Week 44	32 (80.0)	34 (85.0)	33 (84.6)	32 (80.0)
IGA 0				
Week 16	2 (5.0)	10 (25.0)	11 (28.2)	19 (47.5)
Week 28	10 (25.0)	24 (60.0)	21 (53.8)	25 (62.5)
Week 44	19 (47.5)	28 (70.0)	24 (61.5)	27 (67.5)
BSA				
Week 16	32.7 (24.7)	5.9 (8.9)	3.7 (6.7)	6.4 (11.7)
Week 28	8.8 (17.7)	1.6 (3.5)	1.9 (5.0)	5.2 (16.1)
Week 44	4.2 (12.0)	0.7 (1.8)	0.8 (2.3)	4.3 (15.3)
DLOI				
Week 16	14.5 (8.4)	4.1 (5.7)	4.0 (4.6)	4.2 (5.3)

Week 28	5.3 (5.0)	2.4 (3.6)	2.6 (4.5)	3.1 (5.2)
---------	-----------	-----------	-----------	-----------

47 The data of BSA and DLQI was presented as mean (SD), others were presented as n (%). The
48 missing data on PASI 75, IGA 0 and IGA 0/1 were handled by non-responder imputation
49 method, and others using last observation carried forward method. BSA, Body-Surface Area;
50 DLQI, Dermatology Life Quality Index; IGA, Investigator's Global Assessment; PASI,
51 Psoriasis Area and Severity Index; Q8W, receive the treatment every 8 weeks; Q12W, receive
52 the treatment every 12 weeks

53